Pembrolizumab With or Without Sacituzumab Tirumotecan in Participants With Resectable Non Small Cell Lung Cancer Not Achieving Pathological Complete Response

Short Title: MK2870-019

Enrollment Status: Recruiting

NCT #: NCT06312137

Specialty Area: Oncology

Condition Studied: Resectable Non-Small Cell Lung Cancer (NSCLC)

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To find out if adding sacituzumab tirumotecan to pembrolizumab after surgery helps prevent cancer from coming back in people with NSCLC who did not achieve a complete response.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with Non-Small Cell Lung Cancer (NSCLC) that can be removed by surgery (resectable)
Surgery completed but pathological complete response (pCR) not achieved

What's Involved

Participation in the study will include:

Treatment with pembrolizumab with or without sacituzumab tirumotecan given intravenously (IV)
Possible chemotherapy with cisplatin, pemetrexed, gemcitabine, carboplatin, or paclitaxel
Imaging tests to monitor response to treatment
Blood and tissue sample collection
Questionnaires

Principal Investigator

Katharine Thomas, MD

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06312137

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews